BNTC Benitec Biopharma
- 8.9500
- +0.0814+0.92%
- 9.1200
- +0.1700+1.90%
Benitec Biopharma News
Global RNAi Therapeutics Market Insights & Forecasts With Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been add
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel g
Benitec Biopharma 13G Filing Shows Steven Oliveira Reported A 8.89% Passive Stake In The Co As Of April 22
Benitec Biopharma 13G Filing Shows Steven Oliveira Reported A 8.89% Passive Stake In The Co As Of April 22
J.P. Morgan Securities: Maintaining the Benitec Biopharma (BNTC.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $10.00 to $16.00.
J.P. Morgan Securities: Maintaining the Benitec Biopharma (BNTC.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $10.00 to $16.00.
JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $16
JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma with a Market Outperform and raises the price target from $10 to $16.
Benitec Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 128.9% JMP Securities $10 → $16 Maintains Market Outperform 02/15/2024 43.06% JMP Securities $8
Benitec Biopharma's $40 Million Equity Financing Deal
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share
Top Midday Gainers
AGBA Group (AGBA) agreed to merge with artificial intelligence-driven social video platform Triller. The financial-services company said the value of the proposed business combination would be $4 bill
Why Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?
Thursday, Benitec Biopharma Inc (NASDAQ:BNTC) released interim clinical data from the 90-day timepoint following the administration of BB-301 to the study's first subject (Subject 1) treated in the BB
CGC, GENE and HOLO Among Mid-day Movers
Benitec Biopharma Shares Halted On Circuit Breaker To The Upside, Stock Now Up 29%
Benitec Biopharma Shares Halted On Circuit Breaker To The Upside, Stock Now Up 29%
Benitec Biopharma Showcases Encouraging Clinical Trial Results
Benitec Biopharma Reports Positive Data in Early Study for OPMD Treatment
Market-Moving News for April 18th
BPTH: 98% | Bio-Path Holdings shares are trading higher after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to
Why Benitec Biopharma Is Rising In Pre-market?
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday's pre-market session. The market value of their outstanding shares is at $3.5 million. SINTX Techs (NASDAQ:SINT)
Top Premarket Gainers
Tian Ruixiang Holdings (TIRX) shares nearly tripled Thursday premarket following a 7.7% increase in the previous session. MicroCloud Hologram (HOLO) shares surged 42% pre-bell after Wednesday's 5.5% d
Benitec Biopharma Shares Are Trading Higher. The Company Announced a $40 Million Oversubscribed Private Placement Financing and Reported Interim Clinical Data for the First OPMD Subject Treated With BB-301 in Its Phase 1b/2a Study.
Benitec Biopharma Shares Are Trading Higher. The Company Announced a $40 Million Oversubscribed Private Placement Financing and Reported Interim Clinical Data for the First OPMD Subject Treated With BB-301 in Its Phase 1b/2a Study.
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0M
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0M
Analysis
Price Target
No Data
